268 related articles for article (PubMed ID: 17385305)
21. Breast cancer with low FDG uptake: characterization by means of dual-time point FDG-PET/CT.
Zytoon AA; Murakami K; El-Kholy MR; El-Shorbagy E; Ebied O
Eur J Radiol; 2009 Jun; 70(3):530-8. PubMed ID: 18395387
[TBL] [Abstract][Full Text] [Related]
22. Clinical usefulness of dual-time FDG PET-CT in assessment of esophageal squamous cell carcinoma.
Shum WY; Hsieh TC; Yeh JJ; Chen JH; Su CC; Liang JA; Kao CH
Eur J Radiol; 2012 May; 81(5):1024-8. PubMed ID: 21458941
[TBL] [Abstract][Full Text] [Related]
23. Dual time point 2-[18F]fluoro-2'-deoxyglucose positron emission tomography in chronic bacterial osteomyelitis.
Sahlmann CO; Siefker U; Lehmann K; Meller J
Nucl Med Commun; 2004 Aug; 25(8):819-23. PubMed ID: 15266177
[TBL] [Abstract][Full Text] [Related]
24. Potential of dual time point FDG-PET imaging in differentiating malignant from benign pleural disease.
Mavi A; Basu S; Cermik TF; Urhan M; Bathaii M; Thiruvenkatasamy D; Houseni M; Dadparvar S; Alavi A
Mol Imaging Biol; 2009; 11(5):369-78. PubMed ID: 19472014
[TBL] [Abstract][Full Text] [Related]
25. The use of dual-phase 18F-FDG PET in characterizing thyroid incidentalomas.
Hsiao YC; Wu PS; Chiu NT; Yao WJ; Lee BF; Peng SL
Clin Radiol; 2011 Dec; 66(12):1197-202. PubMed ID: 21907336
[TBL] [Abstract][Full Text] [Related]
26. Comparison of early and delayed FDG PET for evaluation of biliary stricture.
Nishiyama Y; Yamamoto Y; Kimura N; Miki A; Sasakawa Y; Wakabayashi H; Ohkawa M
Nucl Med Commun; 2007 Dec; 28(12):914-9. PubMed ID: 18090217
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and Limitations of F-18-fluoro-2-deoxy-D-glucose Positron Emission Tomography to Differentiate Between Malignant and Benign Bone and Soft Tissue Tumors.
Miwa S; Mochizuki T; Yamamoto N; Shirai T; Hayashi K; Takeuchi A; Inatani H; Igarashi K; Higuchi T; Abe K; Taniguchi Y; Aiba H; Ikeda H; Tsuchiya H
Anticancer Res; 2018 Jul; 38(7):4065-4072. PubMed ID: 29970532
[TBL] [Abstract][Full Text] [Related]
28. Evaluation of soft-tissue lesions with (18)F-FDG PET/CT: initial results of a prospective trial.
Leal AL; Etchebehere M; Santos AO; Kalaf G; Pacheco EB; Amstalden EM; Etchebehere EC
Nucl Med Commun; 2014 Mar; 35(3):252-9. PubMed ID: 24300379
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of delayed additional FDG PET imaging in patients with pancreatic tumour.
Nishiyama Y; Yamamoto Y; Monden T; Sasakawa Y; Tsutsui K; Wakabayashi H; Ohkawa M
Nucl Med Commun; 2005 Oct; 26(10):895-901. PubMed ID: 16160649
[TBL] [Abstract][Full Text] [Related]
30. Overexpression of hexokinase-2 in giant cell tumor of bone is associated with false positive in bone tumor on FDG-PET/CT.
Hoshi M; Takada J; Oebisu N; Hata K; Ieguchi M; Nakamura H
Arch Orthop Trauma Surg; 2012 Nov; 132(11):1561-8. PubMed ID: 22825642
[TBL] [Abstract][Full Text] [Related]
31. Bilateral hilar foci on 18F-FDG PET scan in patients without lung cancer: variables associated with benign and malignant etiology.
Karam M; Roberts-Klein S; Shet N; Chang J; Feustel P
J Nucl Med; 2008 Sep; 49(9):1429-36. PubMed ID: 18765585
[TBL] [Abstract][Full Text] [Related]
32. Adrenal masses: the value of additional fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT) in differentiating between benign and malignant lesions.
Okada M; Shimono T; Komeya Y; Ando R; Kagawa Y; Katsube T; Kuwabara M; Yagyu Y; Kumano S; Imaoka I; Tsuchiya N; Ashikaga R; Hosono M; Murakami T
Ann Nucl Med; 2009 Jun; 23(4):349-54. PubMed ID: 19340526
[TBL] [Abstract][Full Text] [Related]
33. Characterization of solitary pulmonary nodules with 18F-FDG PET/CT relative activity distribution analysis.
Zhao L; Tong L; Lin J; Tang K; Zheng S; Li W; Cheng D; Yin W; Zheng X
Eur Radiol; 2015 Jul; 25(7):1837-44. PubMed ID: 25636419
[TBL] [Abstract][Full Text] [Related]
34. 18F-FLT PET performs better than 18F-FDG PET in differentiating malignant uterine corpus tumors from benign leiomyoma.
Yamane T; Takaoka A; Kita M; Imai Y; Senda M
Ann Nucl Med; 2012 Jul; 26(6):478-84. PubMed ID: 22477262
[TBL] [Abstract][Full Text] [Related]
35. Predictability of preoperative 18F-FDG PET for histopathological differentiation and early recurrence of primary malignant intrahepatic tumors.
Song JY; Lee YN; Kim YS; Kim SG; Jin SJ; Park JM; Choi GS; Chung JC; Lee MH; Cho YH; Choi MH; Kim DC; Choi HJ; Moon JH; Lee SH; Jeong SW; Jang JY; Kim HS; Kim BS
Nucl Med Commun; 2015 Apr; 36(4):319-27. PubMed ID: 25564069
[TBL] [Abstract][Full Text] [Related]
36. 18F-FDG PET of common enhancing malignant brain tumors.
Kosaka N; Tsuchida T; Uematsu H; Kimura H; Okazawa H; Itoh H
AJR Am J Roentgenol; 2008 Jun; 190(6):W365-9. PubMed ID: 18492879
[TBL] [Abstract][Full Text] [Related]
37. Quantitative studies using positron emission tomography (PET) for the diagnosis and therapy planning of oncological patients.
Dimitrakopoulou-Strauss A; Strauss L
Hell J Nucl Med; 2006; 9(1):10-21. PubMed ID: 16617388
[TBL] [Abstract][Full Text] [Related]
38. PET evaluation of fatty tumors in the extremity: possibility of using the standardized uptake value (SUV) to differentiate benign tumors from liposarcoma.
Suzuki R; Watanabe H; Yanagawa T; Sato J; Shinozaki T; Suzuki H; Endo K; Takagishi K
Ann Nucl Med; 2005 Dec; 19(8):661-70. PubMed ID: 16444991
[TBL] [Abstract][Full Text] [Related]
39. The role of dual time point FDG PET imaging in the evaluation of solitary pulmonary nodules with an initial standard uptake value less than 2.5.
Macdonald K; Searle J; Lyburn I
Clin Radiol; 2011 Mar; 66(3):244-50. PubMed ID: 21295203
[TBL] [Abstract][Full Text] [Related]
40. Thallium-201 scintigraphy in bone and soft-tissue tumors: a comparison of dynamic, early and delayed scans.
Sugawara Y; Kikuchi T; Kajihara M; Semba T; Ochi T; Fujii T; Mochizuki T; Sakayama K; Nakata S
Ann Nucl Med; 2005 Sep; 19(6):461-8. PubMed ID: 16248382
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]